This is intended as an easy-to-read summary

Feb 01, 2017 · It is the first FDA-approved therapy for central fat accumulation in HIV-infected patients.1 ... Egrifta® (tesamorelin) was added to the MassHealth drug list requiring prior authorization ... therapy. Based on the specific indication, NCCN guidelines listing cabozantinib as a category 1 recommendation as targeted therapy after antiangiogenic ... ................
................